Covid19 : India records 50,040 cases in the past 24 hours
As many as 50,040 more people tested positive for Covid19 in the last 24 hours, taking the cumulative caseload to 3,02,33,183 said the Union health ministry on Sunday. The number is slightly more than yesterday when the infection count rested at 48,698.
On the brighter side, the daily recoveries continue to surpass fresh infections as 57,944 were discharged between Saturday and Sunday. With this, the total number of discharges has gone up to 2,92,51,029 and the recovery rate has improved to 96.75%.
The country attained a milestone on Friday as the total inoculation numbers crossed the 32-crore mark. Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jharkhand, Karnataka, Kerala, Madhya Pradesh, Maharashtra, Rajasthan, Tamil Nadu, Telangana, Odisha, Uttar Pradesh and West Bengal have administered at least one dose of the vaccine to more than 10 lakh beneficiaries of the 18-44 age group.
Prime Minister Narendra Modi expressed satisfaction at an increased pace of Covid vaccination this week and said that it was important to keep this up and also underlined a need to involve NGOs and other organisations in order to expand the drive. PM Modi, while taking stock of the progress of immunisation programme, also directed the officials to work closely with states to ensure that the speed of testing does not go down as testing remains a very important tool to track and contain rising infections in any region.
The Covid-19 vaccine developed by Johnson & Johnson will likely be available in India in small quantities by July this year, sources said. The Association of Healthcare Providers (India) is in the process of privately procuring the vaccine directly from the US-based manufacturer. Johnson & Johnson’s vaccine could arrive in India as early as July, though it will be limited to a few thousand doses initially. The one-shot vaccine will be priced at $25 in India.
Johnson & Johnson has already initiated talks with the Union government to authenticate its manufacturing process and specifications in the country. The US pharmaceutical major had approached the Centre earlier in April with the objective of starting a clinical bridging study in India. Now, according to new rules, it is not mandatory for a vaccine approved by the US drug regulator to conduct bridging trials in India. With this, the vaccine is expected to be cleared for use in India in the coming months.